Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-0.7x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -91.87% |
| Q2 2025 | -73.53% |
| Q1 2025 | -41.22% |
| Q4 2024 | 37.54% |
| Q3 2024 | -26.01% |
| Q2 2024 | -12.34% |
| Q1 2024 | -10.06% |
| Q4 2023 | -0.70% |
| Q3 2023 | 5.58% |
| Q2 2023 | 11.28% |
| Q1 2023 | -7.97% |
| Q4 2022 | 16.23% |
| Q3 2022 | 9.46% |
| Q2 2022 | 62.11% |
| Q1 2022 | 24.74% |
| Q4 2021 | -18.04% |
| Q3 2021 | 7.04% |
| Q2 2021 | 32.46% |
| Q1 2021 | 8.66% |
| Q4 2020 | -45.41% |
| Q3 2020 | 123.50% |
| Q2 2020 | -48.37% |
| Q1 2020 | 63.03% |
| Q4 2019 | -18.04% |
| Q3 2019 | -16.75% |
| Q2 2019 | 69.53% |
| Q1 2019 | 0.32% |
| Q4 2018 | 38.52% |
| Q3 2018 | 21.34% |
| Q2 2018 | -14.62% |
| Q1 2018 | 4.73% |
| Q4 2017 | -14.12% |
| Q3 2017 | 24.41% |
| Q2 2017 | 1.22% |
| Q1 2017 | 5.35% |
| Q4 2016 | -0.94% |
| Q3 2016 | -16.49% |
| Q2 2016 | -28.80% |
| Q1 2016 | -42.70% |
| Q4 2015 | 19.85% |